Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death

INTRODUCTION: The Campath, Calcineurin inhibitor (CNI) reduction, and Chronic allograft nephropathy (3C), a study comparing alemtuzumab versus basiliximab induction immunosuppression in kidney transplants, has found lower acute rejection rate with alemtuzumab but same graft survival. The aim of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Asderakis, Argiris, Sabah, Tarique K., Watkins, William J., Khalid, Usman, Szabo, Laszlo, Stephens, Michael R., Griffin, Sian, Chavez, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039467/
https://www.ncbi.nlm.nih.gov/pubmed/35497810
http://dx.doi.org/10.1016/j.ekir.2022.01.1042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039467/
https://www.ncbi.nlm.nih.gov/pubmed/35497810
http://dx.doi.org/10.1016/j.ekir.2022.01.1042

Ejemplares similares